Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-D-aspartate receptor/glycine-site agonists.
about
A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophreniaHas an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophreniaNeurophysiological and neurochemical animal models of schizophrenia: focus on glutamateN-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?The glutamatergic compounds sarcosine and N-acetylcysteine ameliorate prepulse inhibition deficits in metabotropic glutamate 5 receptor knockout mice.Brief exposure to methamphetamine (METH) and phencyclidine (PCP) during late development leads to long-term learning deficits in rats.Neurophysiological biomarkers for drug development in schizophrenia.Theranostic Biomarkers for SchizophreniaAssociation of schizophrenia onset age and white matter integrity with treatment effect of D-cycloserine: a randomized placebo-controlled double-blind crossover study.Exploring metabolic pathway disruption in the subchronic phencyclidine model of schizophrenia with the Generalized Singular Value DecompositionReviewing the ketamine model for schizophrenia.Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: preliminary evidenceFrom revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment.The antipsychotic-like effects in rodents of the positive allosteric modulator Lu AF21934 involve 5-HT1A receptor signaling: mechanistic studies.Risperidone pretreatment prevents elevated locomotor activity following neonatal hippocampal lesions.Evaluation of an osmotic pump for microdialysis sampling in an awake and untethered rat.Subchronic phencyclidine treatment in adult mice increases GABAergic transmission and LTP threshold in the hippocampus.Targeting prefrontal cortical dopamine D1 and N-methyl-D-aspartate receptor interactions in schizophrenia treatment.GABAB/NMDA receptor interaction in the regulation of extracellular dopamine levels in rodent prefrontal cortex and striatumModulating NMDA Receptor Function with D-Amino Acid Oxidase Inhibitors: Understanding Functional Activity in PCP-Treated Mouse Model.Do NMDA receptor antagonist models of schizophrenia predict the clinical efficacy of antipsychotic drugs?Recent advances in the development of novel pharmacological agents for the treatment of cognitive impairments in schizophrenia.Glycine transporter-1 inhibition promotes striatal axon sprouting via NMDA receptors in dopamine neuronsNeurochemical changes in the rat prefrontal cortex following acute phencyclidine treatment: an in vivo localized (1)H MRS study.Neuroimaging and physiological evidence for involvement of glutamatergic transmission in regulation of the striatal dopaminergic system.Effects of novel, high affinity glycine transport inhibitors on frontostriatal dopamine release in a rodent model of schizophreniaThinking glutamatergically: changing concepts of schizophrenia based upon changing neurochemical models.Overview of glutamatergic neurotransmission in the nervous system.Methodological issues associated with preclinical drug development and increased placebo effects in schizophrenia clinical trials.Managing Negative Symptoms of Schizophrenia: How Far Have We Come?Modulation of striatal dopamine release by glycine transport inhibitors.Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychotic.Chronic phenethylamine hallucinogen treatment alters behavioral sensitivity to a metabotropic glutamate 2/3 receptor agonist.Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of fluvoxamine: role of sigma-1 receptors.Endogenous N-acetylaspartylglutamate reduced NMDA receptor-dependent current neurotransmission in the CA1 area of the hippocampus.Rodent Mismatch Negativity/theta Neuro-Oscillatory Response as a Translational Neurophysiological Biomarker for N-Methyl-D-Aspartate Receptor-Based New Treatment Development in Schizophrenia.
P2860
Q28263502-BBA1ABC2-E724-473F-934A-14A70E6F5EB4Q28275290-847A1D26-16D0-4E9C-91D1-844E6B6BB01CQ30403302-AF7CF49E-5979-42D8-9352-3C6AD7241604Q30474021-3DB1F966-6856-4836-BAEA-365B6ED663CCQ30481854-1095587B-8892-4158-9660-8907EF4C3473Q30481959-80B475CE-009B-4FFC-AFAD-B7A7F56608FAQ30486447-832D5C9D-4022-4C5D-8F53-7A27AE01CD52Q33624412-CF04C927-50A0-4AB7-B54F-41C204D9BBE0Q33900951-ACED7CDD-9283-4FFC-AEE4-D2E90ED6F85BQ33901487-456C549E-6FE8-4774-8B74-550F574FBBDAQ34046060-215A1D55-D2C9-450F-A4E0-D32E21E4A3D7Q34235541-AA1987EE-4DD7-4EF6-A7AB-4F1AE64377BEQ34632695-21D9C32E-3C6C-42D5-8D94-EB1D4ACE9BA7Q34798345-3DAA5395-0445-41F4-97CE-9F9BD7E65578Q35742020-F670AF0A-1553-4D4F-9894-A72DAF095E11Q35933291-28514DA1-001B-4689-B4FB-9F0C2E3B33D5Q36096029-2D90F682-E0ED-4277-9313-7E0BBE2364B9Q36252816-FF0FE9F1-264B-4074-8946-35349EA244D8Q36377150-1CEEC3F4-6992-4374-AA6A-16513AD6548CQ36642660-ACF9CCE8-4C45-4D10-995C-FBB4BBDCA6ECQ36860053-864CC318-7F87-450B-B151-264777DCF141Q36886717-5DB3B0E4-BFF5-4CD4-B09B-467B047BCBABQ37231520-5552FDF5-2098-4317-AEA3-09482A0D2A40Q37319322-218633DB-11EE-4656-B95B-E051B7CE84A9Q37352417-79CBDB9E-4CA2-4C06-B7B7-8F3BA88BCCC8Q37438631-852D0DC0-7BE0-480B-9F62-52A1887B2045Q37794502-BE70AD59-E1B8-47F5-B0BF-4344117B63A7Q37926162-77E3B0AC-37C7-4FFC-98C0-E7E56439C2E8Q38676860-D7FA988A-3CCF-4FD8-8E40-D6A696EBF8A3Q39233330-21B20A8B-25A6-4DC4-BCB7-4A5C6300C1FFQ45249011-3FF2AB32-89A5-4740-866C-34EB105B2551Q46547623-54989362-8834-4D3C-861A-4DFF52BEA299Q46934817-571D161C-F39A-404B-9C86-C5FE311738ADQ46958764-8C5A0402-15EB-46C7-99E9-0071D61A3C98Q48302212-A4FB39CC-7022-4DB1-A24B-DBFB171251FBQ53107602-5E69439B-8770-4EE4-98D9-0E12AEC278B3
P2860
Reversal of phencyclidine-induced dopaminergic dysregulation by N-methyl-D-aspartate receptor/glycine-site agonists.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh-hant
name
Reversal of phencyclidine-indu ...... eceptor/glycine-site agonists.
@en
Reversal of phencyclidine-indu ...... eceptor/glycine-site agonists.
@nl
type
label
Reversal of phencyclidine-indu ...... eceptor/glycine-site agonists.
@en
Reversal of phencyclidine-indu ...... eceptor/glycine-site agonists.
@nl
prefLabel
Reversal of phencyclidine-indu ...... eceptor/glycine-site agonists.
@en
Reversal of phencyclidine-indu ...... eceptor/glycine-site agonists.
@nl
P2093
P2860
P356
P1476
Reversal of phencyclidine-indu ...... eceptor/glycine-site agonists.
@en
P2093
Andrea Balla
Henry Sershen
Ray Suckow
Sarah Burch
P2860
P2888
P304
P356
10.1038/SJ.NPP.1300313
P407
P577
2004-02-01T00:00:00Z